Kornimate/medical-research-clean huggingface dataset:
venlafaxine augmentation in treatment resistant depression

Conditions: Depression

Summary: this is an assessment of the efficacy of venlafaxine-hcl augmentation with the neuroleptic quetiapine in treatment resistant depression.

we examine the efficacy of venlafaxine-hcl augmentation with the neuroleptic quetiapine in treatment resistant depression in a double-blind randomized clinical trial. secondary objective is the evaluation of pharmacogenetic factors contributing to drug efficacy in treatment resistant depression.

Eligibility criteria:
inclusion criteria: * female and male inpatients with a major depressive disorder without psychotic features or with a depressive episode within a bipolar i or ii disorder without psychotic features * ages between 20 and 70 years * total score greater than 18 on the hamilton depression rating scale * documentation of at least one ineffective antidepressant drug trial under adequate dosage for at least 6 weeks in the current episode exclusion criteria: * other psychiatric axis i disorders than those mentioned as inclusion criteria * acute suicidality (item 3 of the hamilton depression rating scale greater than 2) * drug or alcohol addiction * patients with severe hepatic, cardiovascular, neurologic, metabolic or malignant disorders * documentation or report of a previous ineffective treatment trial with venlafaxine, lamotrigine or quetiapine * functional kidney disorders * untreated hypertension * acute treatment with thyroid hormone (less than 3 months) * pregnant or nursing patients * women of childbearing age without effective contraception

Keywords: treatment resistant depression augmentation pharmacogenetics
treatment patterns with targeted therapies in mrcc in sweden - a retrospective analysis of data from national registries

Conditions: Kidney Neoplasms

Summary: the objectives of this study is to investigate treatment patterns and outcomes for sutent and inlyta in mrcc patients in a nationwide population-based setting in sweden.


Eligibility criteria:
inclusion criteria: 1. all patients aged ≥ 18 years with at least one filled prescription of an oral targeted therapy relevant for treating mrcc registered in the swedish prescribed drug register (pdr) between july 1st 2005 and june 30th 2020. the anatomical therapeutic chemical (atc) codes for the oral drugs relevant for treating mrcc are the following: l01xe04 (sunitinib), l01xe05 (sorafenib), l01xe11 (pazopanib), l01xe17 (axitinib), l01xe10 (everolimus), l01xe26 (cabozantinib), l01xe34 (tivozantib), l01xe29 (lenvatinib). 2. the patients identified in the pdr that also are identified in the scr with the international classification of diseases and related health problems (icd)-7 diagnosis codes i800 or i809 and icd-10 codes c64.0 and c64.9 from january 1st 2000 until december 31st 2019;excluding icd-7 code i801 (cancer of the renal pelvis) will be included in the analysis set. exclusion criteria: patients with icd-7 code i801 will be excluded
efficacy and safety of weifuchun tablet in reversing gastric intestinal metaplasia

Conditions: Gastric Intestinal Metaplasia

Summary: the goal of this clinical trial is to investigate the efficacy and safety of weifuchun tablet in treating gastric intestinal metaplasia in helicobacter pylori-negative adults. the main questions it aims to answer are: does weifuchun tablet promote the regression of gastric intestinal metaplasia in individuals without helicobacter pylori infection? what medical problems do participants experience when taking weifuchun tablet? researchers will compare the effectiveness of weifuchun tablet in treating gastric intestinal metaplasia with that of folic acid, as suggested by the chinese consensus on management of gastric epithelial precancerous conditions and lesions (2020). participants will: take weifuchun tablets or folic acid every day for 6 months. visit the clinic once every 4 weeks for checkups and tests.


Eligibility criteria:
inclusion criteria: * patients aged from 18 to 75 years old. * patients with olgim stage ⅱ-ⅳ diagnosed by upper gastrointestinal endoscopy and histopathological examination within the last 3 months. * patients without helicobacter pylori infection, including patients who had successful helicobacter pylori eradication before enrollment. exclusion criteria: * a history of regular use (defined as at least once per week) of non-steroidal anti-inflammatory drugs (nsaids) and/or statins. * a history of stomach surgery (including endoscopic submucosal dissection and endoscopic mucosal resection) or previously diagnosed malignant tumor. * a history of heart failure, renal failure, liver cirrhosis or chronic hepatic failure; patients with contraindications or allergies to the drugs in this study. * breastfeeding or pregnancy. * a history of substance abuse or alcohol abuse within the past one year. * patients with severe mental illness. * refusal to undergo drug treatment. * refusal to sign informed consent.
evaluate the safety, tolerability and pharmacokinetics of bg00010 (neublastin) administered to sciatica participants

Conditions: Sciatica

Summary: the primary objective of the study is to determine the safety/tolerability profile, systemic pk behavior, and immunogenicity of single iv and sc administrations of bg00010 to sciatica participants.


Eligibility criteria:
key inclusion criteria: * must have a diagnosis of unilateral sciatica, determined by the investigator. sciatica symptoms must be present for 6 or more weeks prior to the screening visit. * must have a body mass index (bmi) between 18 kg/m2 and 32 kg/m2. * must rate their pain at \>40 mm on the 100 mm visual analog scale (vas) of the short-form mcgill pain questionnaire (sf-mpq)at the screening and baseline visits. key exclusion criteria: * history of malignancy or clinically significant (as determined by the investigator) allergies, cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic (not related to sciatica), dermatologic, rheumatic/joint, psychiatric, renal, and/or other major disease. * history of signs or symptoms of peripheral neuropathy, other than symptoms of sciatica. * history of severe allergic or anaphylactic drug-related reactions. note: other protocol defined inclusion/exclusion criteria may apply
gypenosides treatment for optic neuritis

Conditions: Optic Neuritis

Summary: the purpose of this study is to determine whether gypenosides are neuroprotective in patients with acute optic neuritis.


Eligibility criteria:
inclusion criteria 1. male and female chinese patients aged ≥18 to ≤60 years 2. patients with a first episode of optic neuritis in the eye of interest 3. first symptoms of optic neuritis ≤28 days prior to the first administration of investigational product 4. best corrected visual acuity in the eye of interest ≤0.8 exclusion criteria 1. pre-existing multiple sclerosis ms or nmo 2. refractive media opacity 3. hyperopia \>5 diopters, myopia \ 3 diopters 4. active tuberculosis, hepatitis, renal insufficiency, uncontrolled hypertension, diabetes mellitus, infection with hiv or syphilis, or any other conditions potentially interfering treatment trial 5. other autoimmune diseases (systemic lupus erythematosus, rheumatoid arthritis, etc) 6. existing other retina or optic nerve diseases 7. pregnant or females who plan to be pregnant during study

Keywords: neuroprotection clinical trial traditional chinese medicine axonal loss jiaogulan gynostemma pentaphyllum optical coherence tomography
external stressors prior to traumatic knee injury in youth athletes.

Conditions: Traumatic Knee Injury

Summary: the aim of this study is to evaluate different aspects of mental stress aspects and its role as a potential risk factor for traumatic knee injury in youth athletes. approximately 300 athletes (age 16-19) 50% women) who are involved in high risk sports (soccer, handball and floorball) will be included. the athletes will record his/hers traumatic knee injury together with information about training regimes and some details on injury mechanism on a web-based form. the form also includes questions about mental stressors, such as club exchange, changed game system in addition to conflict within and outside the family, etc, prior to injury. the present study will contribute new knowledge on levels of muscle function and different aspects of mental stress factors that may be related to traumatic knee injury in young athletes.


Eligibility criteria:
inclusion criteria: male and female sport high school athletes aged 15-19 years participating and competing in soccer, handball, or floorball exclusion criteria: traumatic knee injury prior to sport high school. -
personalizing adoptive cell transfer for solid tumors: towards a new patient-tailored treatment option

Conditions: Carcinoma, Non-Small-Cell Lung

Summary: this is a monocentric prospective observational study. this study will include patients with a diagnosis of non-small cell lung cancer for the collection of blood and tissue specimens.

this study seeks to advance patient-specific cancer immunotherapy, through the ex-vivo generation of tumor-specific t cells recognizing and targeting tumor-specific mutations. the study will enroll 20 adult patients with a diagnosis of non-small cell lung cancer, including those with lymph node involvement. biological samples, including tumor and healthy lung tissue, as well as peripheral blood, will be collected pre-surgery and pre-treatment. the establishment of this sample collection will enable the detailed study of tumor-specific immune responses in non-small cell lung cancer.

Eligibility criteria:
inclusion criteria: * participant is willing and able to provide informed consent for participation in the study. * age: adults aged 18 years or older. * diagnosis: non-small cell lung cancer (stage i-ii, iii), with or without lymph node involvement, ideally with sufficient tumor burden to provide adequate tissue for analysis. in accordance with good clinical practice, patients with early-stage disease will undergo direct surgery, whereas patients with advanced-stage disease will receive neoadjuvant treatment followed by surgery. * ability to attend scheduled follow-up visits, if applicable, for additional peripheral blood sample collection during treatment. exclusion criteria: * presence of any active infection or underlying condition that could compromise the safety of tissue and blood sampling. * prior history of another malignancy that might interfere with data interpretation related to non-small cell lung cancer progression and immune response. * any current use of immunosuppressive medications (e.g., high-dose steroids) which might alter immune response assessments, except as part of non-small cell lung cancer treatment. * pregnancy and breastfeeding

Keywords: immunotherapy precision oncology lung cancer adoptive cell transfer
clinical outcomes of knee replacement

Conditions: Knee Arthroplasty

Summary: the objective of this study is to document the demographic and clinical characteristics and the long-term clinical outcomes of patients who require a robot assisted knee arthroplasty. the hypothesis is that mako® robot assisted surgery replacing one or two compartments of the knee joint has 10 year implant survival and clinical outcomes that are equivalent to other knee replacement systems.


Eligibility criteria:
inclusion criteria: * requires either primary or revision knee replacement surgery because of pain and joint stiffness that interferes with performance of normal daily activities * has failed non-operative management of their joint disease exclusion criteria: * cognitively unable to complete study health-related quality of life forms * pregnant women

Keywords: osteoarthritis joint disease arthritis musculoskeletal disease
a randomized controlled trial comparing urea loaded nanoparticles to placebo: a new concept for cataract management

Conditions: Drug Action Increased

Summary: cataract is the leading cause of vision loss and blindness in the world,surgery is the only available option to correct the problem and the major reasons for low cataract surgical rates include low demand because of fear of surgery, high cost of surgery and poor visual results but new research raises the hope that someday, cataracts could be cured with simple eye drops. this is the first report for preparing urea-loaded nps eye drops for cataract therapy. enhancement of the urea efficacy is accomplished by using polymeric nps based on the amphiphilic block copolymer pluronic®f-127 (pf) which is a hydrophilic nontoxic copolymer widely used as a pharmaceutical excipient for its stabilizing properties and capability to increase the solubility.

51 patients with cataract were included in this study that started at december 2014 to april 2016. all cases collected from out patients' clinic of assiut university hospital these patients were randomized into two groups. group i(control) included 11 cases (22 eyes) used balance salt solution (bss) eye drops. group ii include 40 cases (67 eyes) were treated by the prepared eye drops of urea nps solution. preparation of urea-loaded nanoparticles first the investigators will test the safety of urea as eye drops by injecting urea in concentration of 96 ml/mol in the anterior chamber of 6 rabbit eyes and the other eye of each rabbit will be used as control. after 14 days enucleation of both eyes, then will prepare extracted eye tissue for examination by light and electron microscopes. urea solution will be then prepared for eye drops purpose by enhancing its efficacy using the polymeric nps based on the amphiphilic block copolymer pluronic®f-127 (pf) which is an a-b-a-type triblock copolymer consisting of polyoxyethylene (peo) units (a) and polyoxypropylene (ppo) units (b) with a thermoreversible gelation property that has a hydrophilic nontoxic property widely used as a pharmaceutical excipient for its stabilizing properties and capability to increase the solubility. the eye drop will be prepared by an ionic gelation method using the tripeptide antioxidant glutathione (gsh) with the pluronic®f-127 (pf) as carriers to urea delivery for the target of cataract therapy. pluronic® f127 (pf127), which can be self-assembled into micelles upon increasing concentration or raising temperatures, is used to decorate the water-soluble urea via a chemical reaction. next, the gsh is incorporated into the hydrophobic poly (propylene oxide) compartment of pf127 using electrostatic interactions between the positively charged gsh and the negatively charged pf. the prepared nps were then characterized using transmission electron microscopy (tem). the average size of urea-loaded pf 127/gsh nps was 140 nm.

Eligibility criteria:
inclusion criteria: * all cases were immature cataract at different stages. exclusion criteria: * no complicated cataract included in this study either due to local or systemic diseases.

Keywords: cataract urea-loaded nps tem examination
iron treatment for young children with non-anemic iron deficiency

Conditions: Non-anemic Iron Deficiency

Summary: the pre-school years are critical years for children to acquire early learning skills such as language, fine motor and social skills; this is termed early child development. primary care doctors (family doctors and pediatricians) are in a unique position to identify children with health or developmental problems. screening is the process of testing healthy people for the earliest signs of health problems, followed by treatment, with the expectation that screening will improve the health of those screened. the focus of this research is screening young children for the earliest signs of iron deficiency (low blood iron levels) followed by treatment with oral iron. previous research has shown that children with later stages of iron deficiency have serious delays in their development. some research has shown that these delays may persist into young adulthood often with a significant reduction in intelligence. early stages of iron deficiency may be difficult for parents or doctors to detect, and a blood test is usually needed. however, canadian guidelines do not recommend screening all children for iron deficiency, because there is not enough good quality research to prove that screening is effective. in this study, the investigators will ask parents to allow their child between the ages of 1 to 3 years to have a blood test for iron levels. if the blood level is low, the child will be randomly assigned to receive either oral iron liquid for 4 months plus diet counseling, or a placebo liquid plus diet counseling. a psychologist will measure each child's early learning ability before and after the treatment. if this approach to screening children's blood iron levels followed by treatment improves children's development, parents and doctors may consider that routine blood screening tests are justified. overall, this research is an important step to improving the ways in which primary care doctors can ensure that children have the best start to life-long health and achievement.


Eligibility criteria:
inclusion criteria: * age between 18 and 36 months attending any well child visit * informed parental consent exclusion criteria: * previously diagnosed: developmental disorder, genetic, chromosomal or syndromic condition, chronic medical condition, (with the exception of asthma and allergies), including chronic anemia, iron deficiency or recent oral iron supplementation or treatment * prematurity with a gestational age less than 35 weeks; low birth weight less than 2500 grams * attending the office for an acute illness, such as a viral illness, or other health concern other than well-child assessment * any contraindications to receiving elemental iron (i.e. nhp \[natural health product\], comparator or placebo) * the use of any natural health product containing the same medicinal ingredient(s) as the investigational product * english not spoken to the child in the home or in a child care setting

Keywords: child development screening non-anemic iron deficiency primary care pediatrics prevention and health promotion
best-rpp pilot: screening for esophageal cancer in rural oregon without an endoscopy

Conditions: Esophageal Cancer

Summary: recent advancements in swallowable esophageal cell-collection devices (secd) offer a safe, minimally invasive, accurate, and low-cost alternative to esophageal screening without the need for an upper endoscopy. the best-rpp study aims to evaluate the acceptability and feasibility of using this novel approach to screen for barrett's esophagus (be) and esophageal carcinoma (eac) in rural primary care clinic settings in oregon.

this is a proof-of-concept observational study to pilot the use of an fda approved swallowable esophageal cell-collection device to screen for esophageal cancer in two rural primary care clinics in oregon. the principal investigator will work with clinic staff to gauge the current use and understanding of secds as screening tools for esophageal cancer and to identify 50 patients at each site to approach about secds as an option for screening, for a total of 100 patients. if patients provide their consent and are eligible, they will undergo secd administration for cancer screening in their primary care clinic. the study will evaluate the feasibility of use of this diagnostic tool in rural primary care settings, patient acceptability of screening for esophageal cancer via secd in their primary care clinics, and where there are positive cases, the efficacy of diagnostic and treatment pathways to transitioning patients to tertiary centers for full diagnostic workup.

Eligibility criteria:
inclusion criteria: * signed informed consent * willing and able to comply with the protocol * live in a rural area * chronic gerd dx * 3 or more of the following risk factors: male, age \>50 years white race tobacco smoking obesity family history of be or eac in a first-degree relative exclusion criteria: -
conduction system pacing with ingevity+

Conditions: Bradycardia

Summary: the study is intended to evaluate the safety and effectiveness of the boston scientific ingevity+ cardiac pacing lead when implanted in the left bundle branch area (lbba).

insight is a prospectively defined analysis of ingevity+ leads that have been previously implanted in the lbba for the purpose of anti-bradycardia pacing. the results will provide complication free rate (safety) and lead measurements (performance). data will be gathered by means of a retrospective, multi-center, us only observational chart review to obtain data on ingevity+ leads implanted in the lbba. additional data will be gathered from the pulse generator and from the latitude remote monitoring system for pacing thresholds and r-wave amplitude. consecutive implants will be collected from each site for evaluating the endpoints.

Eligibility criteria:
inclusion criteria for primary analysis: * de novo anti-bradycardia pacing pacemaker implant. * ingevity+ lead implant attempt in the lbba as documented in the medical record at least 90 days ago. * lbbap implant attempt employed a boston scientific sspc series sheath exclusion criteria for primary analysis: -icd and crt-d devices

Keywords: conduction system pacing cardiac physiologic pacing
the effect of soft tissue mobilization and kinesio taping applied to athletics athletes on sports performance

Conditions: Athletic Injuries; Sports Physical Therapy

Summary: the aim of the research is to evaluate the effects of tool-assisted soft tissue mobilization and kinesiology tape applications applied to the hamstring muscle on balance, agility and jumping in athletics athletes.

participants will be divided into 3 groups. kinesiology taping will be applied to the 1st group, and instrument-assisted soft tissue mobilization will be applied to the 2nd group. the 3rd group will be the control group and no application will be made. all 3 groups will participate in regular training. before training, applications will be made to the hamstring muscle on both legs. all 3 groups will be evaluated before, after and 1 month after training, and the 1st and 2nd groups will be evaluated by comparing them with the 3rd group (control group). a 15-minute warm-up period will be given before the measurements. during the post-application measurements, the 1st group will have kinesiological taping. there will be 3-minute rest periods between measurements to prevent fatigue. kinesiology taping; in order to facilitate the muscle, while the subject is standing and his body is flexed to ensure hip flexion, both "i" bands will be applied from the origin to the insertion, with 30% stretching from the medial and lateral, starting from the ischial tuberositas to the border of the popliteal fossa. instrument-assisted soft tissue mobilization; the subject is in a prone position on a bed, with the lower extremity in a neutral position, and a hazelnut-sized amount of lubricant will be applied to the working surface, and will be applied to the skin on the back of the upper leg for 5 minutes, targeting the tissue structures. (hamstring and deep fascia covering this muscle) the pressure and speed will be adjusted according to the tolerance of the subject so as not to cause pain. participants will be administered the unipedal stance test, agility t-test and standing long jump test.

Eligibility criteria:
inclusion criteria * have been doing athletics for the last 6 months and participate in training regularly, * are between the ages of 10-40, * those who train at least 3 days a week, * athletes who have consent to participate in the study (athletes between the ages of 10-18 with consent from their parents) will be included. exclusion criteria * having any history of injury or acute infection, * having a systemic and metabolic disease, * having a history of chronic pain, * having an unhealed or unstable bone fracture, * athletes with allergies, infections or open wounds on the skin will not be included.